Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95.

Abstract

Excessive activation of the N-methyl-d-aspartate (NMDA) receptor and the neurotransmitter dopamine (DA) mediate neurotoxicity and neurodegeneration under many neurological conditions, including Huntington's disease (HD), an autosomal dominant neurodegenerative disease characterized by the preferential loss of medium spiny projection neurons (MSNs) in the striatum. PSD-95 is a major scaffolding protein in the postsynaptic density (PSD) of dendritic spines, where a classical role for PSD-95 is to stabilize glutamate receptors at sites of synaptic transmission. Our recent studies indicate that PSD-95 also interacts with the D1 DA receptor localized in spines and negatively regulates spine D1 signaling. Moreover, PSD-95 forms ternary protein complexes with D1 and NMDA receptors, and plays a role in limiting the reciprocal potentiation between both receptors from being escalated. These studies suggest a neuroprotective role for PSD-95. Here we show that mice lacking PSD-95, resulting from genetic deletion of the GK domain of PSD-95 (PSD-95-ΔGK mice), sporadically develop progressive neurological impairments characterized by hypolocomotion, limb clasping, and loss of DARPP-32-positive MSNs. Electrophysiological experiments indicated that NMDA receptors in mutant MSNs were overactive, suggested by larger, NMDA receptor-mediated miniature excitatory postsynaptic currents (EPSCs) and higher ratios of NMDA- to AMPA-mediated corticostriatal synaptic transmission. In addition, NMDA receptor currents in mutant cortical neurons were more sensitive to potentiation by the D1 receptor agonist SKF81297. Finally, repeated administration of the psychostimulant cocaine at a dose regimen not producing overt toxicity-related phenotypes in normal mice reliably converted asymptomatic mutant mice to clasping symptomatic mice. These results support the hypothesis that deletion of PSD-95 in mutant mice produces concomitant overactivation of both D1 and NMDA receptors that makes neurons more susceptible to NMDA excitotoxicity, causing neuronal damage and neurological impairments. Understanding PSD-95-dependent neuroprotective mechanisms may help elucidate processes underlying neurodegeneration in HD and other neurological disorders.

• Authors: Jingping Zhang, Taixiang Saur, Angela N Duke, Seth G N Grant, Donna M Platt, James K Rowlett, Ole Isacson, Wei-Dong Yao
• Journal: Journal of neurogenetics (J Neurogenet) 2014 Mar-Jun Vol. 28 Issue 1-2 Pg. 98-111 ISSN: 1563-5260 [Electronic] England
• PMID: 24702501 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Benzazepines
• Disks Large Homolog 4 Protein
• Dlg4 protein, mouse
• Dopamine Agonists
• Dopamine and cAMP-Regulated Phosphoprotein 32
• Excitatory Amino Acid Agents
• Membrane Proteins
• Ppp1r1b protein, mouse
• Glutamic Acid
• 6-Cyano-7-nitroquinoxaline-2,3-dione
• SK&F 81297
• Guanylate Kinases
• Magnesium
• Dopamine

Topics

• 6-Cyano-7-nitroquinoxaline-2,3-dione (pharmacology)
• Age Factors
• Animals
• Benzazepines (pharmacology)
• Cell Count
• Corpus Striatum (pathology)
• Disks Large Homolog 4 Protein
• Dopamine (metabolism)
• Dopamine Agonists (pharmacology)
• Dopamine and cAMP-Regulated Phosphoprotein 32 (metabolism)
• Excitatory Amino Acid Agents (pharmacology)
• Excitatory Postsynaptic Potentials (drug effects, genetics)
• Gene Expression Regulation (genetics)
• Glutamic Acid (metabolism)
• Guanylate Kinases (deficiency, genetics)
• Magnesium (pharmacology)
• Membrane Potentials (genetics)
• Membrane Proteins (deficiency, genetics)
• Mice
• Mice, Knockout
• Motor Activity (genetics)
• Movement Disorders (genetics)
• Neurodegenerative Diseases (genetics, pathology)
• Neurons (physiology)